Scientist in a lab working with a multi channel pipette.

Highly selective and potent antiviral agents from the Riboscience Nucleoside Platform have the potential to cure broad-spectrum viral respiratory infections.


PROBLEM:

Influenza and Coronavirus pose pandemic threats—with new variants constantly emerging.

SOLUTION:

Nucleosides are broadly active across variants—potentially offering wider protection as viruses evolve.


PROBLEM:

Drug resistance is a constant challenge. Multiple classes of antiviral agents are required for pandemic preparedness.

SOLUTION:

Riboscience’s nucleosides have demonstrated a high barrier to resistance, with the potential to outperform traditional treatment options.